Company Filing History:
Years Active: 2008-2011
Title: Innovations by Matthias Eberl
Introduction
Matthias Eberl is a notable inventor based in Giessen, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of methods for enhancing isoprenoid biosynthesis and activating immune cells.
Latest Patents
Eberl holds two patents that showcase his innovative work. The first patent focuses on the inactivation of genes in the mevalonate-independent pathway for isoprenoid biosynthesis (MEP pathway). This invention relates to cells and organisms, as well as methods for producing these entities, which involve enriching intermediates of the MEP pathway by deleting or inactivating specific genes. The enriched intermediates can be utilized as substrates in enzyme activity tests and have potential applications in the production of medicaments. The second patent describes organophosphorus compounds that activate gamma/delta T cells. This invention outlines the preparation and uses of these compounds in the activation of immune cells, screening enzyme inhibitors, and treating diseases in both humans and animals.
Career Highlights
Matthias Eberl is associated with Bioagency AG, where he continues to advance his research and innovations. His work has positioned him as a key figure in the biotechnology sector, contributing to the development of new therapeutic approaches.
Collaborations
Eberl collaborates with talented individuals such as Hassan Jomaa and Boran Altincicek, enhancing the scope and impact of his research.
Conclusion
Matthias Eberl's contributions to biotechnology through his patents and collaborations highlight his role as an influential inventor. His work not only advances scientific knowledge but also has the potential to lead to significant medical breakthroughs.